Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy.
Hepatitis B
Tenofovir alafenomide (TAF)
Therapy
Journal
Clinics in liver disease
ISSN: 1557-8224
Titre abrégé: Clin Liver Dis
Pays: United States
ID NLM: 9710002
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
entrez:
1
10
2021
pubmed:
2
10
2021
medline:
5
11
2021
Statut:
ppublish
Résumé
Nucleoside analogues are the drugs most commonly used in the treatment of chronic hepatitis B. They act by inhibiting viral replication and have minimal impact on HBsAg loss. Nucleoside analogues are indicated in patients with chronic hepatitis, cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and in those with extrahepatic manifestations. Real-world experience has been ongoing for more than 10 years, and the efficacy and safety results obtained are similar to those reported in clinical trials. Prolonged use is needed to maintain suppression of viral replication, prevent the development of liver cirrhosis and decompensated cirrhosis, and to decrease the risk of hepatocellular carcinoma.
Identifiants
pubmed: 34593150
pii: S1089-3261(21)00053-2
doi: 10.1016/j.cld.2021.06.003
pii:
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
725-740Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure M. Buti has received research grants from Gilead and has served as advisors for Gilead, Bristol-Myers Squibb, and Novartis. M. Riveiro-Barciela has received research grants from Gilead and served as speaker for Gilead and Grifols. R. Esteban has received research grants from Gilead and has served as advisors for Gilead, Bristol-Myers Squibb, and Novartis.